Voyager Therapeutics, Inc. (FRA:VT6)

Market Cap	188.92M
Revenue (ttm)	26.69M
Net Income (ttm)	-108.06M
Shares Out	n/a
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	101
Open	3.278
Previous Close	3.384
Day's Range	3.278 - 3.278
52-Week Range	2.218 - 6.780
Beta	n/a
RSI	43.75
Earnings Date	Mar 6, 2026

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treat...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 172
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VT6

Financial Performance

Financial numbers in USD